Phase III trial results for cladribine: the CLARITY study


REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY – Oral cladribine appears to be effective in reducing relapse rates and disability progression, according to the preliminary results from the phase III CLARITY (Cladribine tablets treating MS orally) trial (Giovannoni et al. AAN 2009; abstract LBS.001).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page